PFLPhysiological Fitness Landscape

Biomarkers · Inflammation

Fibrinogen

Lower values carry lower risk. Not measured in our NHANES panel; the curve is synthesised from the published association.

Hazard ratio relative to the curve's reference value, as synthesised from the published association.

Published hazard ratio1.37per SD (95% CI 1.28–1.46) · Individual Participant Meta-Analysis (31 Prospective Cohorts)

Where people sit

Population percentiles (mg/dL) by sex and age band. Cycle or source as recorded in the catalogue.

SexAge5th25thMedian75th95thnCycle / source
All20-392202723123564382,1001999-2002
All40-592383003464004982,1001999-2002
All60+2603263764345402,2001999-2002
Allall2352983443984956,4001999-2002
Menall2302923383904823,1001999-2002
Womenall2403043504065083,3001999-2002

What studies found when this marker was changed

Effects on the biomarker reported in the cited studies. They describe what happened in those populations, not a recommendation for anyone. See all catalogued interventions.

TypeInterventionReported effectEvidenceSource
behavioralSmoking cessationLowers plasma fibrinogen by 30-50 mg/dL within 6-12 monthscohortEstruch R, et al. Primary Prevention of Cardiovascular Disease with a Mediterran…
behavioralCessation of cigarette smoking-15% to -25% normalization within 12 monthsprospective cohortTuut M, et al. Atherosclerosis. 1996;126:125-132.
behavioralCigarette smoking and chronic tobacco inhalation+20% to +45% elevationmeta-analysisBembich S, et al. Thromb Haemost. 2004;92:699-707.
environmentalHigh particulate air pollution exposure (PM2.5)+10% to +25% elevationprospective cohortPope CA 3rd, et al. Circulation. 2004;109:71-77.
exerciseRegular moderate aerobic endurance exercise-10% to -20% reduction (30-50 mg/dL)meta-analysisErnst E. Thromb Res. 1993;70:271-274.
pharmacologicFibrate therapy (Fenofibrate 145-200 mg/day)-12% to -20% reductionrctRosenson RS. Atherosclerosis. 2007;190:407-411.

Sources

Map Fibrinogen against another biomarker.